A Study of BG-C477 in Participants With Advanced Solid Tumors
Phase 1
21
about 4.1 years
18+
5 sites in CA, CT, KS +2
What this study is about
Researchers are testing the safety and how well BG-C477 works in people with advanced solid tumors. The trial will last about 1 year and a half, and it may involve taking BG-C477 alone or with other cancer treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BG-C477
- 2.Take Chemotherapy
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
tislelizumab
Primary: Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD), Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 1b: Overall Response Rate (ORR)
Secondary: Phase 1a and 1b: Apparent terminal elimination half-life (t1/2) of BG-C477, Phase 1a and 1b: Disease Control Rate (DCR), Phase 1a and 1b: Duration of Response (DOR), Phase 1a and 1b: Maximum observed plasma concentration (Cmax) of BG-C477 antibody-drug conjugate (ADC), BG-C477 total antibody, and free payload, Phase 1a and 1b: Systemic clearance (CL/F) of BG-C477, Phase 1a and 1b: Time to reach maximum observed plasma concentration (Tmax) of BG-C477, Phase 1a: ORR, Phase 1b: Number of Participants with AEs and SAEs